Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sleep-Disordered Breathing in CTEPH
NCT03074539Completed
- Sponsor
- Medical University of Vienna
- Start
- Feb 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Apnea-Hypopnea Index change under CTEPH treatment at 6 months. Started Feb 2017; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT03074539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074539.